{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:11:21Z","timestamp":1792440681184,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Introduction\/objective<\/jats:title>\n            <jats:p>Janus kinase (JAK) inhibitors have expanded treatment options for rheumatoid arthritis (RA), particularly for patients unresponsive to traditional disease-modifying antirheumatic drugs (DMARDs). However, safety concerns necessitate a thorough post-market evaluation. This study is aimed at comparing the safety profiles of tofacitinib, baricitinib, and upadacitinib using adverse event (AE) reports from the FDA Adverse Event Reporting System (FAERS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A retrospective disproportionality analysis was performed using the FAERS data from 2012 to 2022. The AE reports were categorized into cardiovascular, cancer, respiratory, gastrointestinal, musculoskeletal, and arthralgia-related events. Proportional reporting ratio (PRR) and reporting odds ratios (RORs) with 95% confidence intervals (CIs) were calculated to identify significant safety signals.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Of 273,657 AE reports, tofacitinib had the most (227,144), with increased musculoskeletal-related events (ROR\u2009=\u20091.53, 95% CI 1.49\u20131.57) and a reduced cancer risk (ROR\u2009=\u20090.44, 95% CI 0.41\u20130.47). Baricitinib (9305 reports) showed the highest risk of cardiovascular events (ROR\u2009=\u20091.63, 95% CI 1.50\u20131.78) and cancer (ROR\u2009=\u20092.17, 95% CI 1.83\u20132.58). Upadacitinib (37,208 reports) had elevated risks for respiratory events (ROR\u2009=\u20092.04, 95% CI 1.88\u20132.21) and cancer (ROR\u2009=\u20092.24, 95% CI 2.05\u20132.43).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The distinct safety profiles of these JAK inhibitors suggest that baricitinib poses higher cardiovascular and cancer risks, whereas upadacitinib increases the risk of respiratory and gastrointestinal events. Tofacitinib may be safer for patients with a history of cancer but requires monitoring for musculoskeletal AEs. Personalized risk assessments are critical for safe use of JAK inhibitors.\n<jats:table-wrap>\n                <jats:table>\n                  <jats:tbody>\n                    <jats:tr>\n                      <jats:td align=\"left\" colspan=\"2\">\n                        <jats:bold>Key Points<\/jats:bold>\u2022 <jats:italic>This study provides a comprehensive post-market safety assessment of three JAK inhibitors\u2014tofacitinib, baricitinib, and upadacitinib\u2014using the FAERS data from 2012 to 2022.<\/jats:italic>\u2022 <jats:italic>Distinct safety profiles were identified, with baricitinib showing a higher risk of cardiovascular events and cancer, while upadacitinib posed an increased risk of respiratory and gastrointestinal events.<\/jats:italic>\u2022 <jats:italic>Tofacitinib demonstrated a lower cancer risk than other JAK inhibitors but was associated with more musculoskeletal-related adverse events.<\/jats:italic>\u2022 <jats:italic>These findings emphasize the importance of personalized risk assessment and vigilant monitoring when prescribing JAK inhibitors for rheumatoid arthritis.<\/jats:italic>\n                      <\/jats:td>\n                    <\/jats:tr>\n                  <\/jats:tbody>\n                <\/jats:table>\n              <\/jats:table-wrap>\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s10067-025-07360-9","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T04:02:52Z","timestamp":1739419372000},"page":"1467-1474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Safety of Janus kinase inhibitors in rheumatoid arthritis: a disproportionality analysis using FAERS database from 2012 to 2022"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5848-1609","authenticated-orcid":false,"given":"Bahar","family":"Mikaeili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhair A.","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana L.","family":"Hincapie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff Jianfei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"issue":"4","key":"7360_CR1","doi-asserted-by":"publisher","first-page":"404","DOI":"10.31138\/mjr.301223.eaf","volume":"34","author":"AI Venetsanopoulou","year":"2023","unstructured":"Venetsanopoulou AI et al (2023) Epidemiology and risk factors for rheumatoid arthritis development. Mediterr J Rheumatol 34(4):404\u2013413","journal-title":"Mediterr J Rheumatol"},{"issue":"5","key":"7360_CR2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.3899\/jrheum.200367","volume":"48","author":"KB Almutairi","year":"2021","unstructured":"Almutairi KB et al (2021) The prevalence of rheumatoid arthritis: a systematic review of population-based studies. J Rheumatol 48(5):669\u2013676","journal-title":"J Rheumatol"},{"key":"7360_CR3","doi-asserted-by":"publisher","first-page":"689698","DOI":"10.3389\/fmed.2021.689698","volume":"8","author":"VC Rom\u00e3o","year":"2021","unstructured":"Rom\u00e3o VC, Fonseca JE (2021) Etiology and risk factors for rheumatoid arthritis: a state-of-the-art review. Front Med (Lausanne) 8:689698","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"7360_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.hcl.2010.09.002","volume":"27","author":"JM Kahlenberg","year":"2011","unstructured":"Kahlenberg JM, Fox DA (2011) Advances in the medical treatment of rheumatoid arthritis. Hand Clin 27(1):11\u201320","journal-title":"Hand Clin"},{"key":"7360_CR5","doi-asserted-by":"publisher","unstructured":"Rehman SU et al (2024) Advancing rheumatic disease treatment: a journey towards better lives. Open Health 5(1). https:\/\/doi.org\/10.1515\/ohe-2023-0040","DOI":"10.1515\/ohe-2023-0040"},{"issue":"11","key":"7360_CR6","first-page":"e49738","volume":"15","author":"V Rai","year":"2023","unstructured":"Rai V et al (2023) Futuristic novel therapeutic approaches in the treatment of rheumatoid arthritis. Cureus 15(11):e49738","journal-title":"Cureus"},{"issue":"5","key":"7360_CR7","first-page":"251","volume":"19","author":"V Solitano","year":"2023","unstructured":"Solitano V et al (2023) Advanced combination treatment with biologic agents and novel small molecule drugs for inflammatory bowel disease. Gastroenterol Hepatol (N Y) 19(5):251\u2013263","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"4","key":"7360_CR8","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1080\/13543784.2023.2199919","volume":"32","author":"S Kubo","year":"2023","unstructured":"Kubo S, Nakayamada S, Tanaka Y (2023) JAK inhibitors for rheumatoid arthritis. Expert Opin Investig Drugs 32(4):333\u2013344","journal-title":"Expert Opin Investig Drugs"},{"issue":"2","key":"7360_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","volume":"20","author":"Z Szekanecz","year":"2024","unstructured":"Szekanecz Z et al (2024) Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol 20(2):101\u2013115","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"7360_CR10","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1007\/s13555-024-01166-4","volume":"14","author":"M Mansilla-Polo","year":"2024","unstructured":"Mansilla-Polo M, Morgado-Carrasco D (2024) Biologics versus JAK inhibitors. Part I: cancer risk. A narrative review. Dermatol Ther 14(6):1389\u20131442","journal-title":"Dermatol Ther"},{"issue":"1","key":"7360_CR11","doi-asserted-by":"publisher","first-page":"7140","DOI":"10.1038\/s41598-022-10777-w","volume":"12","author":"L Hoisnard","year":"2022","unstructured":"Hoisnard L et al (2022) Adverse events associated with JAK inhibitors in 126,815 reports from the WHO pharmacovigilance database. Sci Rep 12(1):7140","journal-title":"Sci Rep"},{"issue":"10","key":"7360_CR12","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1080\/14740338.2023.2223955","volume":"22","author":"S Mytheen","year":"2023","unstructured":"Mytheen S et al (2023) Investigating the risk of deep vein thrombosis with JAK inhibitors: a disproportionality analysis using FDA Adverse Event Reporting System Database (FAERS). Expert Opin Drug Saf 22(10):985\u2013994","journal-title":"Expert Opin Drug Saf"},{"issue":"4","key":"7360_CR13","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386(4):316\u2013326","journal-title":"N Engl J Med"},{"issue":"11","key":"7360_CR14","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s40264-023-01333-0","volume":"46","author":"V Yang","year":"2023","unstructured":"Yang V et al (2023) Managing cardiovascular and cancer risk associated with JAK inhibitors. Drug Saf 46(11):1049\u20131071","journal-title":"Drug Saf"},{"issue":"4","key":"7360_CR15","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","volume":"41","author":"A Verden","year":"2018","unstructured":"Verden A et al (2018) Analysis of spontaneous postmarket case reports submitted to the FDA regarding thromboembolic adverse events and JAK inhibitors. Drug Saf 41(4):357\u2013361","journal-title":"Drug Saf"},{"issue":"9","key":"7360_CR16","doi-asserted-by":"publisher","first-page":"4180","DOI":"10.1111\/bcp.15361","volume":"88","author":"Z Dong","year":"2022","unstructured":"Dong Z et al (2022) Thromboembolic events in Janus kinase inhibitors: a pharmacovigilance study from 2012 to 2021 based on the Food and Drug Administration\u2019s Adverse Event Reporting System. Br J Clin Pharmacol 88(9):4180\u20134190","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"7360_CR17","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1177\/1060028019839650","volume":"53","author":"A Mogul","year":"2019","unstructured":"Mogul A, Corsi K, McAuliffe L (2019) Baricitinib: the second FDA-approved JAK inhibitor for the treatment of rheumatoid arthritis. Ann Pharmacother 53(9):947\u2013953","journal-title":"Ann Pharmacother"},{"key":"7360_CR18","doi-asserted-by":"publisher","unstructured":"Wu Y, Wei M, Zhang J (2023) A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib. Front Pharmacol 14. https:\/\/doi.org\/10.3389\/fphar.2023.1200254","DOI":"10.3389\/fphar.2023.1200254"},{"issue":"5","key":"7360_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/clpt.2014.17","volume":"95","author":"H Fang","year":"2014","unstructured":"Fang H et al (2014) Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics. Clin Pharmacol Ther 95(5):496\u2013498","journal-title":"Clin Pharmacol Ther"},{"key":"7360_CR20","unstructured":"FDA. Food and Drug Administration Adverse Event Reporting System (FAERS) quarterly data extract files. [cited 2024 Mar 29]; Available from: https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed 15 Oct 2024"},{"key":"7360_CR21","unstructured":"https:\/\/openvigil.pharmacology.uni-kiel.de\/contingency-table-calculator.php. Accessed 15 Oct 2024"},{"key":"7360_CR22","doi-asserted-by":"crossref","unstructured":"Zou F, et al (2024) Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database. Front Pharmacol 15","DOI":"10.3389\/fphar.2024.1338902"},{"issue":"3","key":"7360_CR23","doi-asserted-by":"publisher","first-page":"e001395","DOI":"10.1136\/rmdopen-2020-001395","volume":"6","author":"SB Cohen","year":"2020","unstructured":"Cohen SB et al (2020) Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open 6(3):e001395","journal-title":"RMD Open"},{"issue":"1","key":"7360_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13075-019-1866-2","volume":"21","author":"J Wollenhaupt","year":"2019","unstructured":"Wollenhaupt J et al (2019) Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther 21(1):89","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"7360_CR25","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1136\/annrheumdis-2021-221276","volume":"81","author":"PC Taylor","year":"2022","unstructured":"Taylor PC et al (2022) Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis 81(3):335\u2013343","journal-title":"Ann Rheum Dis"},{"key":"7360_CR26","unstructured":"U.S. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, c., blood clots, and death for JAK inhibitors. FDA Drug Safety Communication. September 1, 2021. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"},{"issue":"1","key":"7360_CR27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/art.41911","volume":"74","author":"A Deodhar","year":"2022","unstructured":"Deodhar A et al (2022) Safety and efficacy of upadacitinib in patients with active ankylosing spondylitis and an inadequate response to nonsteroidal antiinflammatory drug therapy: one-year results of a double-blind, placebo-controlled study and open-label extension. Arthritis Rheumatol 74(1):70\u201380","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"7360_CR28","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","volume":"80","author":"SB Cohen","year":"2021","unstructured":"Cohen SB et al (2021) Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis 80(3):304\u2013311","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"7360_CR29","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M et al (2014) The global burden of rheumatoid arthritis: estimates from the global burden of disease 2010 study. Ann Rheum Dis 73(7):1316\u20131322","journal-title":"Ann Rheum Dis"},{"key":"7360_CR30","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/1471-2474-14-298","volume":"14","author":"Y He","year":"2013","unstructured":"He Y et al (2013) Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord 14:298","journal-title":"BMC Musculoskelet Disord"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07360-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07360-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07360-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T10:55:07Z","timestamp":1744455307000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07360-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["7360"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07360-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,13]]},"assertion":[{"value":"15 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests, financial or non-financial, that are directly or indirectly related to the work submitted for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}